Type 1 vs. Type 2 Diabetes: Understanding the Key Differences

Type 1 vs. Type 2 Diabetes: Distinct Pathophysiology, Presentation & Management

Both cause hyperglycemia but differ fundamentally in etiology, onset, treatment, and risk profile.

Pathophysiology

FeatureType 1 Diabetes (T1D)Type 2 Diabetes (T2D)
Primary defectAutoimmune β-cell destruction → absolute insulin deficiencyInsulin resistance + relative insulin deficiency (β-cell dysfunction)
GeneticsHLA-DR3/DR4-DQ8 (50% risk); polygenic; <10% familialStrong polygenic (TCF7L2, etc.); >50% have affected first-degree relative
Environmental triggersViral (enterovirus), early diet, vitamin D, hygiene hypothesisObesity, inactivity, aging, intrauterine environment, sleep, stress
Onset agePeak 10-14 yr; any age (LADA = adult-onset T1D)Typically >40 yr; rising in youth with obesity
Body habitusOften lean/weight loss at onsetOften overweight/obese (but not always)
Ketoacidosis riskHigh at diagnosis (30-40%); recurrent if insulin omittedRare (ketosis-prone T2D subset)
C-peptideLow/undetectableNormal/high early; declines over years
AutoantibodiesGAD65, IA-2, ZnT8, IAA, ICA (+ in 85-90% at dx)Negative

Clinical Presentation

  • T1D: Polyuria, polydipsia, polyphagia, weight loss, fatigue, blurred vision — acute/subacute (weeks).
  • T2D: Often asymptomatic; screening detection. Symptoms: polyuria, polydipsia, blurred vision, recurrent infections, acanthosis nigricans, slow healing — insidious (years).

Treatment Paradigms

AspectT1DT2D
InsulinMandatory (basal-bolus MDI or pump)Progressive need (30-50% at 10 yr); not initial
Non-insulin agentsAdjunct only (metformin, SGLT2i, GLP-1 RA for insulin resistance/comorbidities)First-line: Metformin + lifestyle; escalate per ADA/EASD algorithm (GLP-1 RA, SGLT2i for CVD/CKD benefit)
Glucose monitoringCGM standard of care; fingerstick backupCGM if on insulin/high risk; SMBG if oral agents only
Education focusCarb counting, insulin dosing, sick-day rules, DKA prevention, techLifestyle modification, medication adherence, monitoring, complication screening

Complications (Both)

  • Microvascular: Retinopathy, nephropathy, neuropathy.
  • Macrovascular: ASCVD (MI, stroke, PAD) — 2-4x risk.
  • Acute: DKA (T1D > T2D), HHS (T2D > T1D), hypoglycemia (insulin/sulfonylurea).

Key Takeaway

T1D = insulin deficiency (autoimmune) → insulin replacement essential.
T2D = insulin resistance + β-cell failure → lifestyle + progressive pharmacotherapy.
Correct classification guides therapy. Misdiagnosis (LADA as T2D) delays insulin, risks DKA.

Diabetes - Related Articles